Multiple sclerosis: Clinical features, pathophysiology, neuroimaging and future therapies

Future Neurology

Volumn 4, Issue 2, 2009, Pages 229-246

  Borazanci, Aimee Pasqua ^a   Harris, Meghan K ^a   Schwendimann, Robert N ^a   Gonzalez Toledo, Eduardo ^a   Maghzi, Amir H ^b   Etemadifar, Masoud ^b   Alekseeva, Nadejda ^a   Pinkston, James ^a   Kelley, Roger E ^a   Minagar, Alireza ^a  

^a Louisiana State University Health Sciences Center at Shreveport   (United States)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Future; Genetic epidemiology; Multiple sclerosis; Pathogenesis; Therapy

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1 INTERFERON; BETA1A INTERFERON; BG 00012; CALCITRIOL; CLADRIBINE; DACLIZUMAB; DOXYCYCLINE FOSFATEX; FINGOLIMOD; FUMARIC ACID; GADOLINIUM; INTERLEUKIN 12; INTERLEUKIN 16; INTERLEUKIN 17; INTERLEUKIN 23; LAQUINIMOD; MINOCYCLINE; PLACEBO; RITUXIMAB; TERIFLUNOMIDE; UNCLASSIFIED DRUG; VITAMIN D;

ADD ON THERAPY; APPLICATION SITE REACTION; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; FLUSHING; GENE FUNCTION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HEARTBURN; HUMAN; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; MULTIPLE SCLEROSIS; NAUSEA; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RELAPSE; REVIEW; RHINOPHARYNGITIS; RIGOR; SIBLING; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

EID: 67149121884     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.4.2.229     Document Type: Review

References (122)

1. Weinshenker BG: Epidemiology of multiple sclerosis. Neurol. Clin. 14, 291-308 (1996).
2. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N. Eng. J. Med. 343, 938-952 (2000).
3. Peterson JW, Trapp BD: Neuropathobiology of multiple sclerosis. Neurol. Clin. 23, 107-129 (2005).
4. Frohman EM, Racke MK, Raine CS: Multiple sclerosis - the plaque and its pathogenesis. N. Engl. J. Med. 354, 942-955 (2006).
5. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L: Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
6. Bar-Or A: Immunology of multiple sclerosis. Neurol. Clin. 23, 149-175 (2005).
7. Minagar A, Alexander JS: Blood - brain barrier disruption in multiple sclerosis. Mult. Scler. 9, 540-549 (2003).
8. Minagar A, Ostanin D, Long AC et al.: Serum from patients with multiple sclerosis downregulates occludin and VE-cadherin expression in cultured endothelial cells. Mult. Scler. 9, 235-238 (2003).
9. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133-146 (2003).
10. + T cells. Nat. Immunol. 3, 549-557 (2002).
11. Zhang GX, Yu S, Gran B et al.: Role of IL-12 receptor β 1 in regulation of T cell response by APC in experimental autoimmune encephalomyelitis. J. Immunol. 171, 4485-4492 (2003).
12. Kebir H, Kreymborg K, Ifergan I et al.: Human TH17 lymphocytes promote blood - brain barrier disruption and central nervous system inflammation. Nat. Med. 13, 1173-1175 (2007).
13. + cells through the boost of the Th2 phenotype, the inhibition of Th17 response and the prevalence of naturally occurring T regulatory cells. Mol. Immunol. 45, 4008-4019 (2008).
14. Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J: Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J. Clin. Invest. 102, 1045-1050 (1998).
15. Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH: Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J. Immunol. 171, 2725-2733 (2003).
16. Monson NL, Brezinschek HP, Brezinschek RI et al.: Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients. J. Neuroimmunol. 158, 170-181 (2005).
17. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707-717 (2000).
18. McDonald WI, Compston A, Edan G et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50, 121-127 (2001).
19. Poser CM, Paty DW, Scheinberg L et al.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13, 227-231 (1983).
20. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ: EDMUS, a European Database for Multiple Sclerosis. J. Neurol. Neurosurg. Psychiatry. 55, 671-676 (1992).
21. Lublin FD: Clinical features and diagnosis of multiple sclerosis. Neurol. Clin. 23, 1-15 (2005).
22. Kantarci O, Wingerchuk D: Epidemiology and natural history of multiple sclerosis: new insights. Curr. Opin. Neurol. 19, 248-254 (2006).
23. Confavreux C: Denning the natural history of MS: the need for complete data and rigorous definitions. Mult. Scler. 14, 289-291 (2008).
24. Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46, 907-911 (1996).
25. Wingerchuk DM: Neuromyelitis optica. Adv. Neurol 98, 319-333 (2006).
26. Weinshenker BG, Wingerchuk DM, Vukusic S et al.: Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann. Neurol. 59, 566-569 (2006).
27. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH: A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 346, 158-164 (2002).
28. Kappos L, Polman CH, Freedman MS et al.: Treatment with interferon-β-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67, 1242-1249 (2006).
29. Minagar A, Sheremata WA: Glossopharyngeal neuralgia and MS. Neurology 54, 1368-1370 (2000).
30. Galton F: The history of twins as a criterion of the relative powers of nature and nurture. J. Anthropol. Inst. Gt Brit. Ire. 5, 391-406 (1875).
31. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC; Canadian Collaborative Study Group: Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl Acad. Sci. USA 100, 12877-12882 (2003).
32. Ristori G, Cannoni S, Stazi MA et al.: Multiple sclerosis in twins from continental Italy and Sardinia: a nationwide study. Ann. Neurol. 59, 27-34 (2006).
33. Compston A: Genetic epidemiology of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 62, 553-561 (1997).
34. Sadovnick AD, Baird PA: Multiple sclerosis: updated risks for relatives. Am. J. Med. Genet. 29, 533-541 (1988).
35. Ebers GC, Koopman WJ, Hader W et al.: The natural history of multiple sclerosis: a geographically based study 8. Familial multiple sclerosis. Brain 123, 641-649 (2000).
36. Ebers GC, Sadovnick AD, Risch NJ: A genetic basis for familial aggregation in multiple sclerosis. Nature 377, 150-151 (1995).
37. Ebers GC, Sadovnick AD, Dyment DA et al.: Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet 363, 1773-1774 (2004).
38. Dyment DA, Yee IM, Ebers GC, Sadovnick AD; Canadian Collaborative Study Group: Multiple sclerosis in stepsiblings: recurrence risk and ascertainment. J. Neurol. Neurosurg. Psychiatry 77, 258-259 (2006).
39. Robertson NP, O'Riordan JI, Chataway J et al.: Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. Lancet 349, 1587-1590 (1997).
40. Hupperts R, Broadley S, Mander A, Clayton D, Compston DA, Robertson NP: Patterns of disease in concordant parent - child pairs with multiple sclerosis. Neurology 57, 290-295 (2001).
41. Kantarci OH, Barcellos LF, Atkinson EJ et al.: Men transmit MS more often to their children vs women: the Carter effect. Neurology 67, 305-310 (2006).
42. Herrera BM, Ramagopalan SV, Orton S et al.: Parental transmission of MS in a population-based Canadian cohort. Neurology 69, 1208-1212 (2007).
43. Ramagopalan SV, Herrera BM, Bell JT et al.: Parental transmission of HLA-DRB1*15 in multiple sclerosis. Hum. Genet. 122, 661-663 (2008).
44. Herrera BM, Ramagopalan SV, Lincoln MR et al.: Parent-of-origin effects in MS. Observations from avuncular pairs. Neurology 71(11), 799-803 (2008).
45. Hoppenbrouwers IA, Liu F, Aulchenko YS et al.: Maternal transmission of multiple sclerosis in a Dutch population. Arch. Neurol. 65, 345-348 (2008).
46. Vogler S, Goedde R, Miterski B et al.: Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis. J. Mol. Med. 83, 806-811 (2005).
47. Vogler S, Pahnke J, Rousset S et al.: Uncoupling protein 2 has protective function during experimental autoimmune encephalomyelitis. Am. J. Pathol. 168, 1570-1575 (2006).
48. Chalmers RM, Robertson N, Compston DAS, Harding AE: Sequence of mitochondrial DNA in patients with multiple sclerosis. Ann. Neurol. 40, 239-243 (1996).
49. Kalman B, Alder H: Is the mitochondrial DNA involved in determining susceptibility to multiple sclerosis? Acta Neurol. Scand. 98, 232-237 (1998).
50. Harding AE, Sweeney MG, Miller DH et al.: Occurrence of a multiple sclerosis like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 115, 979-989 (1992).
51. Morison IM, Paton CJ, Cleverley SD: The imprinted gene and parent-of-origin effect database. Nucleic Acids Res. 29, 275-277 (2001).
52. Ramagopalan SV, Valdar W, Dyment DA et al.; Canadian Collaborative Study Group: No effect of preterm birth on the risk of multiple sclerosis: a population based study. BMC Neurol. 31(3), 181-184 (2008).
53. Polman CH, Reingold SC, Edan G et al.: Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann. Neurol. 58, 840-846 (2005).
54. Swanton JK, Fernando K, Dalton CM et al.: Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J. Neurol. Neurosurg. Psychiatry 77, 830-833 (2006).
55. Swanton JK, Rovira A, Tintore M et al.: MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 6, 677-686 (2007).
56. Simon JH, Li D, Traboulsee A et al.: Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am. J. Neuroradiol. 27, 455-461 (2006).
57. Traboulsee A, Li DK: Conventional MR imaging. Neuroimaging. Clin. N. Am. 18, 651-673 (2008).
58. Robertson WD, Li DK, Mayo JR, Fache JS, Paty DW: Assessment of multiple sclerosis lesions by magnetic resonance imaging. Can. Assoc. Radiol. J. 38, 177-182 (1987).
59. Kermode AG, Tofts PS, Thompson AJ et al.: Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 40, 229-235 (1990).
60. Cotton F, Weiner HL, Jolesz FA, Guttmann CR: MRI contrast uptake in new lesions in relapsing-remitting MS followed at weekly intervals. Neurology 60, 640-646 (2003).
61. Lai M, Hodgson T, Gawne-Cain M et al.: A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 60, 339-341 (1996).
62. Masdeu JC, Moreira J, Trasi S, Visintainer P, Cavaliere R, Grundman M: The open ring. A new imaging sign in demyelinating disease. J. Neuroimaging 6, 104-107 (1996).
63. Liu C, Edwards S, Gong Q, Roberts N, Blumhardt LD: Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 66, 323-330 (1999).
64. Pirko I, Lucchinetti CF, Sriram S, Bakshi R: Gray matter involvement in multiple sclerosis. Neurology 68, 634-642 (2007).
65. Filippi M, Mastronardo G, Rocca MA, Pereira C, Comi G: Quantitative volumetric analysis of brain magnetic resonance imaging from patiems with multiple sclerosis. J. Neurol. Sci. 158, 148-153 (1998).
66. Kutzelnigg A, Lucchinetti CF, Stadelmann C et al.: Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128(Pt 11), 2705-2712 (2005).
67. Fisher E, Lee JC, Nakamura K, Rudick RA: Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann. Neurol. 64, 255-265 (2008).
68. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ: Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125(Pt 8), 1676-1695 (2002).
69. Zivadinov R, Reder AT, Filippi M et al.: Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 71, 136-144 (2008).
70. van Walderveen MA, Barkhof F, Tas MW et al.: Patterns of brain magnetic resonance abnormalities on T2-weighted spin echo images in clinical subgroups of multiple sclerosis: a large cross-sectional study. Eur. Neurol. 40, 91-98. (1998)
71. Altmann DR, Jasperse B, Barkhof F et al.: Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology DOI: 10.1212/01.wn1.0000335765.35346.Fc (2008).
72. Miller DH, Soon D, Fernando KT et al.; AFFIRM Investigators: MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 268, 1390-1401 (2007).
73. Narayana PA: Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J. Neuroimaging 15(Suppl. 4), 46S-57S (2005).
74. Lin A, Ross BD, Harris K, Wong W: Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx 2, 197-214 (2005).
75. Bitsch A, Bruhn H, Vougioukas V et al.: Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am. J. Neuroradiol. 20, 1619-1627 (1999).
76. Gonzalez-Toledo E, Kelley RE, Minagar A: Role of magnetic resonance spectroscopy in diagnosis and management of multiple sclerosis. Neurol. Res. 28, 280-283 (2006).
77. Bakshi R, Thompson AJ, Rocca MA et al.: MRI in multiple sclerosis: current status and future prospects. Lancet Neurol. 7, 615-625 (2008).
78. Bot JC, Barkhof F, Polman CH et al.: Spinal cord abnormalities in recently diagnosed IMS patients: added value of spinal MRI examination. Neurology 62, 226-233 (2004).
79. Bot JC, Blezer EL, Kamphorst W et al.: The spinal cord in multiple sclerosis: relationship of high-spatial-resolution quantitative MR imaging findings to histopathologic results. Radiology 2, 531-540 (2004).
80. Bot JC, Barkhof F, Lycklama à Nijeholt G et al.: Differentiation of multiple sclerosis from other inflammatory disorders and cerebrovascular disease: value of spinal MR imaging. Radiology 223, 46-56 (2002).
81. Tartaglino LM, Friedman DP, Flanders AE, Lublin FD, Knobler RL, Liem M: Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 195, 725-732 (1995).
82. Dalton CM, Brex PA, Miszkiel KA et al.: New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann. Neurol. 53, 673-676 (2003).
83. O'Riordan JI, Losseff NA, Phatouros C et al.: Asymptomatic spinal cord lesions in clinically isolated optic nerve, brain stem, and spinal cord syndromes suggestive of demyelination. J. Neurol. Neurosurg. Psychiatry 64, 353-357 (1998).
84. Rose JW, Watt HE, White AT, Carlson NG: Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. 56, 864-867 (2004).
85. Montalban X, Wynn D, Kaufman M et al.: Preliminary CHOICE results: a Phase 2, randomized, double-blind, placebo-controlled multicenter study of subcutaneous daclizumab in patients with active, relasping forms of multiple sclerosis on interferon β. Program and abstracts of the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Prague, Czech Republic, 11-14 October (2007) (Abstract 50).
86. Coles AJ, Cox A, Le Page E et al.: The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 253, 98-108 (2006).
87. Coles AJ, Compston DA, Selmaj KW et al.; CAMMS223 Trial Investigators: Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med. 359, 1786-1801 (2008).
88. Jones JL, Coles AJ: Campath-1H treatment of multiple sclerosis. Neurodegener. Dis. 5, 27-31 (2008).
89. Dalakas MC: B cells as therapeutic targets in autoimmune neurological disorders. Nat. Clin. Pract. Neurol. 4(10), 557-567 (2008).
90. Racke MK: The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr. Opin. Neurol. 21(Suppl. 1), S9-S18 (2008).
91. Oh S, Cudrici C, Ito T, Rus H: B-cells and humoral immunity in multiple sclerosis. Implications for therapy. Immunol. Res. 40, 224-234 (2008).
92. Nikbin B, Bonab MM, Khosravi F, Talebian F: Role of B cell follicles with germinal center in the meninges of patients with relapsing-remitting multiple sclerosis (RRMS) [AAN abstract S12.003]. Neurology. 68(Suppl. 1) A99 (2007).
93. McLaughlin KA, Wucherpfennig KW: B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv. Immunol. 98, 121-149 (2008).
94. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C: An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64, 1270-1272 (2005).
95. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons JA: Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 180, 63-70 (2006).
96. Bar-Or A, Calabresi PA, Arnold D et al.: Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, Phase I trial. Ann. Neurol. 63, 395-400 (2008).
97. Hauser SL, Waubant E, Arnold DL et al.; HERMES Trial Group: B-cell depletion with rituximab in relapsing - remitting multiple sclerosis. N. Engl. J. Med. 358, 676-688 (2008).
98. Fan LW, Pang Y, Lin S, Rhodes PG, Cai Z: Minocydine attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neuroscience 133, 159-168 (2005).
99. Giuliani F, Hader W, Yong VW: Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell - microglia interaction. J. Leukoc. Biol. 78, 135-143 (2005).
100. Giuliani F, Metz LM, Wilson T, Fan Y, Bar-Or A, Yong VW: Additive effect of the combination of glatiramer acetate and minocycline in a model of MS. J. Neuroimmunol. 158, 213-221 (2005).
101. Yong VW: Prospects for neuroprotection in multiple sclerosis. J. Neuroimmunol. 9, 864-872 (2004).
102. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW: Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. Brain 125, 1297-1308 (2002).
103. Minagar A, Alexander JS, Schwendimann RN et al.: Combination therapy with interferon β-1a and doxycycline in multiple sclerosis: an open-label trial. Arch. Neurol. 65, 199-204 (2008).
104. Mark BL, Carson JA: Vitamin D and autoimmune disease - implications for practice from the multiple sclerosis literature. J. Am. Diet. Assoc. 106, 418-424 (2006).
105. Hauser SL, Weiner HL, Che M, Shapiro ME, Gilles F, Letvin NL: Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation. J. Immunol. 132, 1276-1281 (1984).
106. Lemire JM, Archer DC: 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 87, 1103-1107 (1991).
107. Lemire JM: Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J. Steroid Biochem. Mol. Biol. 53, 599-602 (1995).
108. Hayes CE, Nashold FE, Spach KM, Pedersen LB: The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. (Noisy-le-grand). 49, 277-300 (2003).
109. Tokuda N, Levy RB: 1,25-dihydroxyvitamin D3 stimulates phagocytosis but suppresses HLA-DR and CD13 antigen expression in human mononuclear phagocytes. Proc. Soc. Exp. Biol. Med. 211, 244-250 (1996).
110. Brinkmann V, Davis MD, Heise CE et al.: The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453-21457 (2002).
111. Mandala S, Hajdu R, Bergstrom J et al.: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296, 346-349 (2002).
112. Kappos L, Antel J, Comi G et al.; FTY720 D2201 Study Group: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355(11), 1124-1140 (2006).
113. Vandermeeren M, Janssens S, Borgers M, Geysen J: Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells. Biochem. Biophys. Res. Commun. 234, 19-23 (1997).
114. Kappos L, Miller DH, MacManus DG et al.: Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: results of a Phase 2 study. J. Neurol. 253, 27 (2006).
115. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E: A double-blind, placebo-controlled, randomized trial of cladribine in relapsing - remitting multiple sclerosis. Proc. Assoc. Am. Physicians. 111, 35-44 (1999).
116. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J: The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl Acad. Sci. USA 93, 1716-1720 (1996).
117. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E: Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344, 9-13 (1994).
118. Rice GP, Filippi M, Comi G: Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54, 1145-1155 (2000).
119. Cherwinski HM, Cohn RG, Cheung P et al.: The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J. Pharmacol. Exp. Ther. 275, 1043-1039 (1995).
120. O'Connor PW, Li D, Freedman MS et al.: Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group: A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66, 894-900 (2006).
121. Yang JS, Xu LY, Xiao BG, Hedlund G, Link H: Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats. J. Neuroimmunol. 156, 3-9 (2004).
122. Comi G, Pulizzi A, Rovaris M et al.; LAQ/5062 Study Group: Effect of laquinimod on MRI-monitored disease activity in patients with relapsing - remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet 37, 2085-2092 (2008).